Sacituzumab govitecan治疗上皮性癌:I/II期IMMU-132-01篮式试验最终安全性与疗效结果
该I/II期篮式试验评估了Trop-2抗体药物偶联物Sacituzumab govitecan(SG)在难治性转移性上皮性癌患者中的安全性和疗效。总体安全人群(n=495)中,最常见治疗相关不良事件为恶心、中性粒细胞减少、腹泻、疲劳和脱发,≥3级中性粒细胞减少发生率为42.4%。在子宫内膜癌和小细胞肺癌队列中观察到客观缓解,验证了Trop-2作为实体瘤广泛靶点的潜力。
要点
- SG在总体安全人群中安全性可控,最常见不良事件为恶心、中性粒细胞减少和腹泻。
- 子宫内膜癌和小细胞肺癌队列分别观察到22.2%和17.7%的客观缓解率。
- UGT1A1*28纯合子患者中性粒细胞减少发生率数值上高于杂合子或野生型患者。
核心结论
- SG在难治性转移性上皮性癌患者中表现出与既往报道一致的安全性特征,并在多个癌种队列中观察到疗效,验证了Trop-2作为实体瘤广泛靶点的价值。
研究设计与样本
- I/II期多中心篮式试验(NCT01631552),纳入难治性转移性上皮性癌患者,静脉给予SG(8、10、12或18 mg/kg),第1天和第8天给药,21天为一周期,直至疾病进展或不可耐受毒性。
- 总体安全人群(OSP)n=495,中位年龄61岁,女性占68%;UGT1A1*28纯合子n=46(9.3%)。
- 疗效评估队列包括小细胞肺癌、结直肠癌、食管癌、子宫内膜癌、胰腺导管腺癌和去势抵抗性前列腺癌(每组n>10)。
主要发现
- 41例(8.3%)因不良事件永久终止治疗;治疗相关严重不良事件75例(15.2%),最常见为发热性中性粒细胞减少(4.0%)和腹泻(2.8%)。
- 最常见治疗相关不良事件:恶心62.6%、中性粒细胞减少57.8%、腹泻56.2%、疲劳48.3%、脱发40.4%。
- ≥3级中性粒细胞减少和发热性中性粒细胞减少发生率分别为42.4%和5.3%。
- 中性粒细胞减少(所有级别)在UGT1A1*28纯合子中为28/46(60.9%),杂合子为69/180(38.3%),野生型为59/177(33.3%)。
- 部分缓解见于子宫内膜癌(4/18,22.2% ORR)和小细胞肺癌(11/62,17.7% ORR),1例去势抵抗性前列腺癌患者达到完全缓解(1/11,9.1% ORR)。
临床怎么用
- SG在难治性上皮性癌中具有可管理的安全性,但需重点关注中性粒细胞减少和腹泻,尤其UGT1A1*28纯合子患者。
- 对于子宫内膜癌和小细胞肺癌等Trop-2表达相关癌种,SG显示出具有临床意义的抗肿瘤活性。
局限性
- 为I/II期篮式试验,部分队列样本量较小(如去势抵抗性前列腺癌n=11,子宫内膜癌n=18),疗效结果需进一步验证。
- 疗效终点为研究者评估,非独立中心盲态评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease cohorts not published previously. PATIENTS AND METHODS: Patients with refractory metastatic epithelial cancers received intravenous SG (8, 10, 12, or 18 mg/kg) on days 1 and 8 of 21-day cycles until disease progression or unacceptable toxicity. Endpoints for the OSP included safety and pharmacokinetic parameters with investigator-evaluated objective response rate (ORR per RECIST 1.1), duration of response, clinical benefit rate, progression-free survival, and overall survival evaluated for cohorts (n > 10 patients) of small-cell lung, colorectal, esophageal, endometrial, pancreatic ductal adenocarcinoma, and castrate-resistant prostate cancer. RESULTS: In the OSP (n = 495, median age 61 years, 68% female; UGT1A1∗28 homozygous, n = 46; 9.3%), 41 (8.3%) permanently discontinued treatment due to adverse events (AEs). Most common treatment-related AEs were nausea (62.6%), diarrhea (56.2%), fatigue (48.3%), alopecia (40.4%), and neutropenia (57.8%). Most common treatment-related serious AEs (n = 75; 15.2%) were febrile neutropenia (4.0%) and diarrhea (2.8%). Grade ≥3 neutropenia and febrile neutropenia occurred in 42.4% and 5.3% of patients, respectively. Neutropenia (all grades) was numerically more frequent in UGT1A1∗28 homozygotes (28/46; 60.9%) than heterozygotes (69/180; 38.3%) or UGT1A1∗1 wild type (59/177; 33.3%). There was one treatment-related death due to an AE of aspiration pneumonia. Partial responses were seen in endometrial cancer (4/18, 22.2% ORR) and small-cell lung cancer (11/62, 17.7% ORR), and one castrate-resistant prostate cancer patient had a complete response (n = 1/11; 9.1% ORR). CONCLUSIONS: SG demonstrated a toxicity profile consistent with previous published reports. Efficacy was seen in several cancer cohorts, which validates Trop-2 as a broad target in solid tumors.
引用
- Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021. PMID: 33741442. doi:10.1016/j.annonc.2021.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。